Spots Global Cancer Trial Database for ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Official Title: ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Study ID: NCT05059444
Conditions
Interventions
Study Description
Brief Summary: The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Redwood City, Redwood City, California, United States
Contact Details
Name: Study Director
Affiliation: Guardant Health, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
